title: Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.
abstract: BACKGROUND
  Intermittent infusion of vancomycin is widely used to treat late-onset sepsis in neonates. On the other hand, the continuous infusion of vancomycin could improve bactericidal efficacy since its action is time dependent.
  
  
  OBJECTIVE
  To evaluate a simplified dosage schedule for continuous-infusion vancomycin therapy.
  
  
  METHODS
  Prospective study in premature neonates (<34 weeks) with suspected coagulase-negative staphylococci (CoNS) sepsis. Before antibiotics at time zero (T0), serum creatinine was measured and blood cultures were collected. Vancomycin dosage began with 25 mg/kg/day or 15 mg/kg/day (period 1) and 30 mg/kg/day or 20 mg/kg/day (period 2) depending on whether serum creatinine was below or above 90 mumol/l. Two days after beginning treatment (first timepoint: T1), serum vancomycin was measured and second blood cultures were collected.
  
  
  RESULTS
  Between June 2002 and December 2005, 145 neonates were evaluated. At birth, the median (interquartile range) body weight was 920 (500-1160) g and gestational age was 28 (26-29) weeks. At T1, serum vancomycin was within the required range in 74.5% of neonates (108/145). Serum vancomycin levels were higher in period 2 than in period 1 (20 mg/l vs 13 mg/l, p<0.05). At T0, 55% (80/145) of blood cultures were positive for CoNS, but 71% (57/80) were negative at T1. Four days after beginning treatment, 92% of subjects had recovered without removing the central venous catheter.
  
  
  CONCLUSIONS
  Using this simplified dosage schedule, bactericidal efficacy was maintained and most subjects had serum vancomycin concentrations within the therapeutic range.
authors.affiliation: CHU de Montpellier, Service de Néonatologie (Pediatrie 2), Hôpital Arnaud de Villeneuve, Montpellier, France.
authors.forename: O
authors.initials: O
authors.lastname: Plan
authors.forename: G
authors.initials: G
authors.lastname: Cambonie
authors.forename: E
authors.initials: E
authors.lastname: Barbotte
authors.forename: P
authors.initials: P
authors.lastname: Meyer
authors.forename: C
authors.initials: C
authors.lastname: Devine
authors.forename: C
authors.initials: C
authors.lastname: Milesi
authors.forename: O
authors.initials: O
authors.lastname: Pidoux
authors.forename: M
authors.initials: M
authors.lastname: Badr
authors.forename: J C
authors.initials: JC
authors.lastname: Picaud
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D007262:Infusions, Intravenous; D008297:Male; D011446:Prospective Studies; D018805:Sepsis / Q000097:blood / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D003404:Creatinine